Equities research analysts at Evercore ISI began coverage on shares of Qiagen (NASDAQ:QGEN) in a note issued to investors on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock.
A number of other analysts have also weighed in on QGEN. Cowen reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Qiagen in a research note on Thursday, September 28th. Zacks Investment Research raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Tuesday, October 10th. Commerzbank reissued a “buy” rating on shares of Qiagen in a research report on Tuesday, November 7th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Finally, Deutsche Bank restated a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $34.19.
Qiagen (NASDAQ QGEN) traded up $0.57 during trading hours on Wednesday, reaching $31.93. 951,768 shares of the company were exchanged, compared to its average volume of 801,450. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The stock has a market capitalization of $7,330.00, a price-to-earnings ratio of 81.87, a PEG ratio of 1.71 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings data on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The company had revenue of $364.00 million during the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the firm earned $0.29 earnings per share. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. sell-side analysts predict that Qiagen will post 1.25 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of QGEN. Acrospire Investment Management LLC grew its stake in shares of Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after purchasing an additional 349 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of Qiagen by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after purchasing an additional 20 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Qiagen by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after purchasing an additional 225 shares during the period. Koch Industries Inc. purchased a new position in shares of Qiagen during the 2nd quarter valued at approximately $231,000. Finally, Hartford Investment Management Co. purchased a new position in shares of Qiagen during the 3rd quarter valued at approximately $231,000. 62.24% of the stock is currently owned by institutional investors and hedge funds.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.